[This retracts the article DOI: 10.3892/ol.2018.8225.].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176339 | PMC |
| http://dx.doi.org/10.3892/ol.2018.9405 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The analysis of molecular classification of pulmonary neuroendocrine tumors and relationship between YAP1 and efficacy.
Invest New Drugs
January 2025
Postgraduate Training Base Alliance, Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, 310022, Zhejiang, China.
A novel molecular classification for small cell lung cancer (SCLC) has been established utilizing the transcription factors achaete-scute homologue 1 (ASCL1), neurogenic differentiation factor 1 (NeuroD1), POU class 2 homeobox 3 (POU2F3), and yes-associated protein 1 (YAP1). This classification was predicated on the transcription factors. Conversely, there is a paucity of information regarding the distribution of these markers in other subtypes of pulmonary neuroendocrine tumors (PNET).
View Article and Find Full Text PDFBackground: Recent transcriptome analysis has demonstrated increased expression of Vascular Endothelial Growth Factor receptor-1 (VEGFR-1/FLT1) and decreased expression of VEGFR-2/KDR in AD brain. Increased expression of VEGFR-1 and its ligand VEGFB were associated with a more rapid rate of cognitive decline, providing evidence of a potential link between aberrant VEGFR-1 expression in AD pathogenesis. In this study, we explored the potential role of aberrant VEGFR-1 expression in neurons on AD pathology.
View Article and Find Full Text PDFDoublecortin-like kinase 1 promotes stem cell-like properties through the Hippo-YAP pathway in prostate cancer.
Int J Med Sci
January 2025
Department of Urology, Kidney and Urology Center, the Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China.
Doublecortin-like kinase 1 (DCLK1) has been revealed to be involved in modulating cancer stemness and tumor progression, but its role in prostate cancer (PCa) remains obscure. Castration-resistant and metastatic PCa exhibit aggressive behaviors, and current therapeutic approaches have shown limited beneficial effects on the overall survival rate of patients with advanced PCa. This study aimed to investigate the biological role and potential molecular mechanism of DCLK1 in the progression of PCa.
View Article and Find Full Text PDFEfficacy of metformin and verteporfin treatment alone or in combination in a murine head and neck cancer xenograft model.
Eur J Oral Sci
January 2025
Department of Oral Bioscience and Dental Public Health, International College of Dentistry, Walailak University, Bangkok, Thailand.
Despite treatment advances, head and neck squamous cell carcinoma (HNSCC) still poses a significant global health challenge. Combination therapies have emerged as more effective strategies than traditional chemotherapy in clinical practice by improving tumor response rates and patient survival while minimizing treatment-related toxicity. This study investigates the anticancer effects of metformin and verteporfin (Yes-associated protein 1 [YAP1] inhibitor) alone or in combination in HNSCC using vitro and in vivo approaches.
View Article and Find Full Text PDFYAP-driven malignant reprogramming of oral epithelial stem cells at single cell resolution.
Nat Commun
January 2025
Gleiberman Head and Neck Cancer Center, Moores Cancer Center, University of California San Diego Health, La Jolla, CA, 92037, USA.
Tumor initiation represents the first step in tumorigenesis during which normal progenitor cells undergo cell fate transition to cancer. Capturing this process as it occurs in vivo, however, remains elusive. Here we employ spatiotemporally controlled oncogene activation and tumor suppressor inhibition together with multiomics to unveil the processes underlying oral epithelial progenitor cell reprogramming into tumor initiating cells at single cell resolution.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!